Department of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Department of Materials Science and Engineering, Stanford University, Stanford, CA 94305, USA.
Sci Transl Med. 2021 Jan 27;13(578). doi: 10.1126/scitranslmed.abd6726.
Insulin was first isolated almost a century ago, yet commercial formulations of insulin and its analogs for hormone replacement therapy still fall short of appropriately mimicking endogenous glycemic control. Moreover, the controlled delivery of complementary hormones (such as amylin or glucagon) is complicated by instability of the pharmacologic agents and complexity of maintaining multiple infusions. In this review, we highlight the advantages and limitations of recent advances in drug formulation that improve protein stability and pharmacokinetics, prolong drug delivery, or enable alternative dosage forms for the management of diabetes. With controlled delivery, these formulations could improve closed-loop glycemic control.
胰岛素早在近一个世纪前就被首次分离出来，但用于激素替代治疗的胰岛素及其类似物的商业制剂仍未能恰当地模拟内源性血糖控制。此外，补充激素（如胰淀素或胰高血糖素）的控制递送受到药理制剂的不稳定性和维持多次输注的复杂性的影响。在这篇综述中，我们重点介绍了改进蛋白质稳定性和药代动力学、延长药物递送或实现替代剂型以管理糖尿病的药物制剂方面的最新进展的优势和局限性。通过控制递送，这些制剂可以改善闭环血糖控制。
